{"transactions":[{"id":703373,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-07-24T21:00:08.000Z","date":"2026-07-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":15405,"price":0.8976,"value":13827.528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":95944,"source":{"system":"sec-edgar","filing":"0001727756-26-000008","document":"form4-07242026_050705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000172775626000008/form4-07242026_050705.xml","form_type":"4"}},{"id":717263,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-07-03T00:05:08.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2370,"price":0.6507,"value":1542.159,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":111349,"source":{"system":"sec-edgar","filing":"0001727756-26-000006","document":"form4-07022026_080704.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000172775626000006/form4-07022026_080704.xml","form_type":"4"}},{"id":818990,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-04-02T20:15:19.000Z","date":"2026-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":2876,"price":0.5975,"value":1718.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":112363,"source":{"system":"sec-edgar","filing":"0001727756-26-000004","document":"form4-04022026_040407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000172775626000004/form4-04022026_040407.xml","form_type":"4"}},{"id":950213,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-05T13:30:07.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":2448,"price":0.5801,"value":1420.0848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":115239,"source":{"system":"sec-edgar","filing":"0001727756-26-000002","document":"form4-01052026_080104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000172775626000002/form4-01052026_080104.xml","form_type":"4"}},{"id":1026540,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-10-02T21:05:09.000Z","date":"2025-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2453,"price":0.335,"value":821.755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":117687,"source":{"system":"sec-edgar","filing":"0001727756-25-000003","document":"form4-10022025_051005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000172775625000003/form4-10022025_051005.xml","form_type":"4"}},{"id":1094334,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-07-02T20:30:42.000Z","date":"2025-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2453,"price":1.65,"value":4047.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":120140,"source":{"system":"sec-edgar","filing":"0001415889-25-019058","document":"form4-07022025_040708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588925019058/form4-07022025_040708.xml","form_type":"4"}},{"id":1182658,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-04-02T20:15:20.000Z","date":"2025-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":6044,"price":1.58,"value":9549.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":122593,"source":{"system":"sec-edgar","filing":"0001415889-25-009632","document":"form4-04022025_040413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588925009632/form4-04022025_040413.xml","form_type":"4"}},{"id":1296213,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-23T21:15:12.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":230000,"derivative":{"exercise_price":2.77,"expiration_date":"2035-01-20","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001415889-25-001926","document":"form4-01232025_040106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588925001926/form4-01232025_040106.xml","form_type":"4"}},{"id":1318314,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-01-02T22:45:10.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4857,"price":3.35,"value":16270.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":128637,"source":{"system":"sec-edgar","filing":"0001415889-25-000155","document":"form4-01022025_050105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588925000155/form4-01022025_050105.xml","form_type":"4"}},{"id":1393748,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-02T20:15:11.000Z","date":"2024-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":109,"price":1.88,"value":204.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":133494,"source":{"system":"sec-edgar","filing":"0001415889-24-024382","document":"form4-10022024_041005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588924024382/form4-10022024_041005.xml","form_type":"4"}},{"id":1459350,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-07-03T20:15:16.000Z","date":"2024-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":138,"price":1.92,"value":264.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":133603,"source":{"system":"sec-edgar","filing":"0001415889-24-019175","document":"form4-07032024_040713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588924019175/form4-07032024_040713.xml","form_type":"4"}},{"id":1548657,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-03T21:06:20.000Z","date":"2024-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":157,"price":3.08,"value":483.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":133741,"source":{"system":"sec-edgar","filing":"0001415889-24-010070","document":"form4-04032024_090410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000141588924010070/form4-04032024_090410.xml","form_type":"4"}},{"id":1691025,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T22:21:06.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":62500,"derivative":{"exercise_price":2.33,"expiration_date":"2033-12-31","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001209191-24-000469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919124000469/doc4.xml","form_type":"4"}},{"id":1691024,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-03T22:21:06.000Z","date":"2024-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":157,"price":2.28,"value":357.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":133898,"source":{"system":"sec-edgar","filing":"0001209191-24-000469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919124000469/doc4.xml","form_type":"4"}},{"id":1691023,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-03T22:21:06.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant to the Reporting Person of a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":134055,"source":{"system":"sec-edgar","filing":"0001209191-24-000469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919124000469/doc4.xml","form_type":"4"}},{"id":1708791,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-15T22:10:21.000Z","date":"2023-12-13","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":62500,"derivative":{"exercise_price":2.7,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001209191-23-058818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919123058818/doc4.xml","form_type":"4"}},{"id":1708790,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-15T22:10:21.000Z","date":"2023-12-13","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant to the Reporting Person of a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":71555,"source":{"system":"sec-edgar","filing":"0001209191-23-058818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919123058818/doc4.xml","form_type":"4"}},{"id":1764932,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-10-04T20:23:57.000Z","date":"2023-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1184,"price":3.83,"value":4534.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":9055,"source":{"system":"sec-edgar","filing":"0001209191-23-051948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919123051948/doc4.xml","form_type":"4"}},{"id":1835232,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-07-05T20:34:14.000Z","date":"2023-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":151,"price":4.1,"value":619.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":10239,"source":{"system":"sec-edgar","filing":"0001209191-23-041120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919123041120/doc4.xml","form_type":"4"}},{"id":1926872,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-04-04T21:05:00.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":480,"price":3.08,"value":1478.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split."}],"balance_after":10390,"source":{"system":"sec-edgar","filing":"0001209191-23-022801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919123022801/doc4.xml","form_type":"4"}},{"id":2065851,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-04T22:09:22.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":1720,"price":0.15,"value":258.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":220252,"source":{"system":"sec-edgar","filing":"0001209191-23-001098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919123001098/doc4.xml","form_type":"4"}},{"id":2143683,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:05:02.000Z","date":"2022-09-30","kind":"tax_withholding","acquired":false,"shares":1719,"price":0.223,"value":383.337,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":221972,"source":{"system":"sec-edgar","filing":"0001209191-22-052356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919122052356/doc4.xml","form_type":"4"}},{"id":2213963,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-07-05T21:01:22.000Z","date":"2022-06-30","kind":"tax_withholding","acquired":false,"shares":1719,"price":0.389,"value":668.691,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":223691,"source":{"system":"sec-edgar","filing":"0001209191-22-040788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919122040788/doc4.xml","form_type":"4"}},{"id":2307277,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-04T21:09:46.000Z","date":"2022-03-31","kind":"tax_withholding","acquired":false,"shares":3469,"price":0.65,"value":2254.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":225410,"source":{"system":"sec-edgar","filing":"0001209191-22-022530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919122022530/doc4.xml","form_type":"4"}},{"id":2324051,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2022-03-18T21:10:08.000Z","date":"2022-03-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on March 31, 2023 and 6.25% every three months thereafter, ending on March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2032-03-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-020066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919122020066/doc4.xml","form_type":"4"}},{"id":2324050,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-18T21:10:08.000Z","date":"2022-03-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc."}],"balance_after":228879,"source":{"system":"sec-edgar","filing":"0001209191-22-020066","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919122020066/doc4.xml","form_type":"4"}},{"id":2447516,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T21:40:26.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":1250,"price":1.02,"value":1275.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":153879,"source":{"system":"sec-edgar","filing":"0001209191-22-000858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919122000858/doc4.xml","form_type":"4"}},{"id":2553924,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:12:27.000Z","date":"2021-09-30","kind":"tax_withholding","acquired":false,"shares":1480,"price":1.39,"value":2057.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":155129,"source":{"system":"sec-edgar","filing":"0001209191-21-058519","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121058519/doc4.xml","form_type":"4"}},{"id":2578449,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2021-09-03T21:34:41.000Z","date":"2021-09-02","kind":"grant","acquired":true,"shares":60860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date."}],"balance_after":60860,"derivative":{"exercise_price":1.68,"expiration_date":"2031-09-02","underlying":"Common Stock","underlying_shares":60860},"source":{"system":"sec-edgar","filing":"0001209191-21-054836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121054836/doc4.xml","form_type":"4"}},{"id":2578448,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:34:41.000Z","date":"2021-09-02","kind":"grant","acquired":true,"shares":60859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date."}],"balance_after":156609,"source":{"system":"sec-edgar","filing":"0001209191-21-054836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121054836/doc4.xml","form_type":"4"}},{"id":2643666,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-07-02T20:36:27.000Z","date":"2021-06-30","kind":"tax_withholding","acquired":false,"shares":3083,"price":3.51,"value":10821.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":95750,"source":{"system":"sec-edgar","filing":"0001209191-21-044979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121044979/doc4.xml","form_type":"4"}},{"id":2760439,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-02T16:14:59.000Z","date":"2021-03-31","kind":"tax_withholding","acquired":false,"shares":1945,"price":6.84,"value":13303.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":98833,"source":{"system":"sec-edgar","filing":"0001209191-21-024411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121024411/doc4.xml","form_type":"4"}},{"id":2835140,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2021-02-24T21:39:30.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":68162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025."}],"balance_after":68162,"derivative":{"exercise_price":8.33,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":68162},"source":{"system":"sec-edgar","filing":"0001209191-21-013818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121013818/doc4.xml","form_type":"4"}},{"id":2835139,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-24T21:39:30.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":29213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025."}],"balance_after":100778,"source":{"system":"sec-edgar","filing":"0001209191-21-013818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121013818/doc4.xml","form_type":"4"}},{"id":2918929,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-05T21:32:39.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":2378,"price":1.58,"value":3757.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":286262,"source":{"system":"sec-edgar","filing":"0001209191-21-001094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121001094/doc4.xml","form_type":"4"}},{"id":3015468,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-02T20:32:14.000Z","date":"2020-09-30","kind":"tax_withholding","acquired":false,"shares":2378,"price":1.66,"value":3947.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":288640,"source":{"system":"sec-edgar","filing":"0001209191-20-053157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120053157/doc4.xml","form_type":"4"}},{"id":3090807,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-07-02T20:25:19.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":2378,"price":1.73,"value":4113.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":291018,"source":{"system":"sec-edgar","filing":"0001209191-20-040306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120040306/doc4.xml","form_type":"4"}},{"id":3155999,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-05-08T21:54:26.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024."}],"balance_after":112500,"derivative":{"exercise_price":1.95,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001209191-20-028038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120028038/doc4.xml","form_type":"4"}},{"id":3155998,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-05-08T21:54:26.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024."}],"balance_after":293401,"source":{"system":"sec-edgar","filing":"0001209191-20-028038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120028038/doc4.xml","form_type":"4"}},{"id":3180284,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-04-07T21:22:56.000Z","date":"2020-04-06","kind":"tax_withholding","acquired":false,"shares":3763,"price":1.4,"value":5268.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":180901,"source":{"system":"sec-edgar","filing":"0001209191-20-023810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023810/doc4.xml","form_type":"4"}},{"id":3180283,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-04-07T21:22:56.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":97682,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":184664,"source":{"system":"sec-edgar","filing":"0001209191-20-023810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023810/doc4.xml","form_type":"4"}},{"id":3180282,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-04-07T21:22:56.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":27530,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":86982,"source":{"system":"sec-edgar","filing":"0001209191-20-023810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023810/doc4.xml","form_type":"4"}},{"id":3185764,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-04-02T20:41:04.000Z","date":"2020-03-31","kind":"tax_withholding","acquired":false,"shares":1940,"price":2.68,"value":5199.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":59452,"source":{"system":"sec-edgar","filing":"0001209191-20-022588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120022588/doc4.xml","form_type":"4"}},{"id":3215143,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":57086,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024."}],"balance_after":57086,"derivative":{"exercise_price":6.81,"expiration_date":"2030-02-24","underlying":"Common Stock","underlying_shares":57086},"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215142,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":45020,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023."}],"balance_after":45020,"derivative":{"exercise_price":6.37,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":45020},"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215141,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":17772,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022."}],"balance_after":17772,"derivative":{"exercise_price":10.73,"expiration_date":"2028-02-27","underlying":"Common Stock","underlying_shares":17772},"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215140,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":7701,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021."}],"balance_after":7701,"derivative":{"exercise_price":9.1,"expiration_date":"2027-08-08","underlying":"Common Stock","underlying_shares":7701},"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215139,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":23696,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The ordinary shares underlying this option vest over a period of four years (25% on November 11, 2017 and 6.25% every three months thereafter) ending December 31, 2020."}],"balance_after":23696,"derivative":{"exercise_price":14.43,"expiration_date":"2026-11-15","underlying":"Common Stock","underlying_shares":23696},"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215138,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":54086,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":61392,"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215137,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-03-11T21:57:35.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":7306,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":7306,"source":{"system":"sec-edgar","filing":"0001209191-20-018228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018228/doc4.xml","form_type":"4"}},{"id":3215017,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":96365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":4.03,"expiration_date":"2030-02-24","underlying":"Ordinary Shares","underlying_shares":96365},"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3215016,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":75997,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":3.77,"expiration_date":"2029-01-01","underlying":"Ordinary Shares","underlying_shares":75997},"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3215015,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":6.35,"expiration_date":"2028-02-27","underlying":"Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3215014,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021."}],"balance_after":0,"derivative":{"exercise_price":5.39,"expiration_date":"2027-08-08","underlying":"Ordinary Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3215013,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this option vest over a period of four years (25% on November 11, 2017 and 6.25% every three months thereafter) ending December 31, 2020."}],"balance_after":0,"derivative":{"exercise_price":8.54,"expiration_date":"2026-11-15","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3215012,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":91303,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents Foamix restricted stock unit awards (\"Foamix RSUs\") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an \"Adjusted RSU Award\") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3215011,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:41:15.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":12333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."}],"balance_after":91303,"source":{"system":"sec-edgar","filing":"0001209191-20-018202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018202/doc4.xml","form_type":"4"}},{"id":3251940,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options","published_at":"2020-02-24T18:39:23.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":96365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024."}],"balance_after":96365,"derivative":{"exercise_price":4.03,"expiration_date":"2030-02-24","underlying":"Ordinary Shares","underlying_shares":96365},"source":{"system":"sec-edgar","filing":"0001209191-20-012199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120012199/doc4.xml","form_type":"4"}},{"id":3251939,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-24T18:39:23.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":41299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024."}],"balance_after":103636,"source":{"system":"sec-edgar","filing":"0001209191-20-012199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120012199/doc4.xml","form_type":"4"}},{"id":3321402,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2020-01-03T17:23:57.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":514,"price":3.28,"value":1685.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person."}],"balance_after":62337,"source":{"system":"sec-edgar","filing":"0001209191-20-001245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120001245/doc4.xml","form_type":"4"}},{"id":3400364,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2019-10-02T16:20:34.000Z","date":"2019-09-30","kind":"tax_withholding","acquired":false,"shares":673,"price":3.07,"value":2066.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person."}],"balance_after":62851,"source":{"system":"sec-edgar","filing":"0001209191-19-051671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119051671/doc4.xml","form_type":"4"}},{"id":3467281,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2019-07-03T16:26:42.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":951,"price":2.35,"value":2234.85,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":63524,"source":{"system":"sec-edgar","filing":"0001209191-19-041101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119041101/doc4.xml","form_type":"4"}},{"id":3563661,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2019-04-03T16:38:10.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":1696,"price":3.75,"value":6360.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":64475,"source":{"system":"sec-edgar","filing":"0001209191-19-023170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119023170/doc4.xml","form_type":"4"}},{"id":3707331,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2019-01-03T16:08:13.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":75997,"price":3.77,"value":286508.69,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date."}],"balance_after":75997,"derivative":{"exercise_price":3.77,"expiration_date":"2029-01-01","underlying":"Ordinary Shares","underlying_shares":75997},"source":{"system":"sec-edgar","filing":"0001178913-19-000048","document":"zk1922434.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891319000048/zk1922434.xml","form_type":"4"}},{"id":3707330,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2019-01-03T16:08:13.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":32569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereaf-ter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date."}],"balance_after":66171,"source":{"system":"sec-edgar","filing":"0001178913-19-000048","document":"zk1922434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891319000048/zk1922434.xml","form_type":"4"}},{"id":3766251,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP R&D"}}],"security":"Ordinary Shares","published_at":"2018-11-13T06:16:33.000Z","date":"2018-11-08","kind":"sale","acquired":false,"shares":683,"price":4.58,"value":3128.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":33602,"source":{"system":"sec-edgar","filing":"0001178913-18-002900","document":"zk1822262.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318002900/zk1822262.xml","form_type":"4"}},{"id":3848219,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP R&D"}}],"security":"Ordinary Shares","published_at":"2018-08-09T16:05:22.000Z","date":"2018-08-08","kind":"sale","acquired":false,"shares":2715,"price":5.68,"value":15421.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discre-tionary trade by the reporting person."}],"balance_after":34285,"source":{"system":"sec-edgar","filing":"0001178913-18-002363","document":"zk1822017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318002363/zk1822017.xml","form_type":"4"}},{"id":4026374,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP R&D"}}],"security":"Options","published_at":"2018-02-28T16:12:27.000Z","date":"2018-02-27","kind":"grant","acquired":true,"shares":30000,"price":6.35,"value":190500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022."}],"balance_after":30000,"derivative":{"exercise_price":6.35,"expiration_date":"2028-02-27","underlying":"Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001178913-18-000726","document":"zk1821309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000726/zk1821309.xml","form_type":"4"}},{"id":4026373,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":28717,"kind":"person","name":"Stuart Iain","position":1,"cik":"0001727756","reported_name":"Stuart Iain","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP R&D"}}],"security":"Ordinary Shares","published_at":"2018-02-28T16:12:27.000Z","date":"2018-02-27","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 27,000 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security and (ii) the 10,000 ordinary shares sub-ject to unvested restricted share units granted on February 27, 2018 and first reported on this Form 4."}],"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001178913-18-000726","document":"zk1821309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318000726/zk1821309.xml","form_type":"4"}}]}